4th Circ. Backs Dismissal of Takeda Whistleblower Suit

Law360, Los Angeles (January 11, 2013, 7:42 PM EST) -- The Fourth Circuit on Friday ruled that a Takeda Pharmaceuticals North America Inc. sales leader could not proceed with his whistleblower lawsuit against the pharmaceutical giant accusing it of allowing off-label use to overbill Medicare for a stomach acid drug because his thrice-amended complaint failed to allege specific violations of the False Claims Act.

In a 17-page decision, the a three-judge panel unanimously ruled that Nathan’s allegations concerning the promotion of Kapidex to doctors fell “far short of the pleading standards” set by the Federal Rules...
To view the full article, register now.




Case Information

Case Title

Nathan v. Takeda Pharmaceuticals North America, Inc.

Case Number



Virginia Eastern

Nature of Suit

Other Statutory Actions


Anthony J Trenga

Date Filed

September 14, 2009

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.